Tamera Douglas
Gerontology · Little Rock, ARNPI 1881270122
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.6% of the total across 121 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Sumitomo Pharma America, Inc. at 31.4% of the total. Reporting peaked in 2023 at $1,547 and has fallen 85.7% since, to $222 in 2025. Among gerontology clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 121 payments — averaging $24.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$921
- Myriad Genetic Laboratories, Inc.$437
- Johnson & Johnson$434
- Dendreon Pharmaceuticals LLC$231
- Astellas Pharma US Inc$178
- Accord Healthcare, Inc.$137
- plus $596 from 14 others
What the payments were for
- Food & beverage$2,80496%
- Education$1304%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 52 | $921 |
| Myriad Genetic Laboratories, Inc. | 3 | $437 |
| Johnson & Johnson | 20 | $434 |
| Dendreon Pharmaceuticals LLC | 5 | $231 |
| Astellas Pharma US Inc | 5 | $178 |
| Accord Healthcare, Inc. | 1 | $137 |
| AbbVie | 5 | $98 |
| Pfizer | 6 | $97 |
| Novartis | 5 | $84 |
| Amgen | 2 | $36 |
| Halozyme Inc | 2 | $35 |
| Bayer | 2 | $34 |
| Axonics, Inc. | 2 | $33 |
| Blue Earth Diagnostics | 2 | $33 |
| Tolmar, Inc. | 2 | $29 |
| Coloplast | 2 | $28 |
| Procept Biorobotics Corporation | 1 | $28 |
| Merck | 2 | $28 |
| Verity Pharmaceuticals Inc. | 1 | $19 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,934 in reported general payments places this provider in the 90th percentile of 89 gerontology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 17 | $240,512 |
| GemtesaVibegron | 140 | $80,458 |
| OrgovyxRelugolix | 25 | $66,613 |
| MyrbetriqMirabegron | 56 | $34,165 |
| Tamsulosin Hcl | 752 | $10,824 |
| Solifenacin Succinate | 134 | $3,552 |
| Finasteride | 273 | $3,192 |
| Testosterone Cypionate | 58 | $2,218 |
| Trospium Chloride | 34 | $2,095 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 78 | $1,980 |
| Estradiol | 37 | $1,915 |
| Oxybutynin Chloride ErOxybutynin Chloride | 165 | $1,914 |
| Potassium Citrate ErPotassium Citrate | 31 | $1,467 |
| Tolterodine Tartrate ErTolterodine Tartrate | 23 | $896 |
| Trimethoprim | 21 | $893 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $178 | $274,67773 claims |
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $921 | $147,071165 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 89 gerontology providers in Arkansas.
Other gerontology in Little Rock
- Rebekka AmickLittle Rock$6K
- Samantha WattLittle Rock$3K
- Tiffany RecklingLittle Rock$2K
- Keely SparksLittle Rock$2K
- Robin BallLittle Rock$2K
- Lindsey ReynoldsLittle Rock$2K
- Valerie BeaversLittle Rock$2K
- Jennifer ThompsonLittle Rock$2K
- Franklin TondjoLittle Rock$1K
- Julia MullenaxLittle Rock$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.